Comparison 2. Gefitinib versus placebo (Asian subgroup).

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 HR Overall survival	2		Hazard Ratio (Fixed, 95% CI)	Subtotals only
1.1 G(250) vs P = 2nd line	1		Hazard Ratio (Fixed, 95% CI)	0.66 [0.48, 0.91]
1.2 G(250) vs P = Maintenance	1		Hazard Ratio (Fixed, 95% CI)	0.88 [0.68, 1.14]
2 HR Progression‐free survival	2		Hazard Ratio (Fixed, 95% CI)	Subtotals only
2.1 G(250) vs P = 2nd line	1		Hazard Ratio (Fixed, 95% CI)	0.69 [0.52, 0.91]
2.2 G(250) vs P = Maintenance	1		Hazard Ratio (Fixed, 95% CI)	0.42 [0.33, 0.54]
3 1‐year survival rate	1		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
3.1 G(250) vs P = 2nd line	1	342	Risk Ratio (M‐H, Fixed, 95% CI)	1.75 [1.20, 2.55]
4 Overall response rate	2		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
4.1 G(250) vs P = 2nd line	1	306	Risk Ratio (M‐H, Random, 95% CI)	6.03 [1.46, 24.91]
4.2 G(250) vs P = Maintenance	1	296	Risk Ratio (M‐H, Random, 95% CI)	35.00 [4.86, 252.15]